Vol 55, No 1 (2021)
Research Paper
Published online: 2020-12-11

open access

Page views 1419
Article views/downloads 2599
Get Citation

Connect on Social Media

Connect on Social Media

Variability in melatonin concentration in blood serum of patients with episodic migraine: a pilot study

Anna Zduńska1, Joanna Cegielska1, Sebastian Zduński2, Michał Białobrzewski1, Jan Kochanowski1
Pubmed: 33306192
Neurol Neurochir Pol 2021;55(1):81-90.


Aim of study. This study was aimed at assessing the possible effect of melatonin concentration on migraine. The serum concentration profile of melatonin in patients with diagnosed episodic migraine in the interictal period was compared to the profile in patients without migraine. Then, a correlation between the frequency and duration of migraine attacks, and the possible relationship between these parameters and melatonin levels in individual patients, was established.

Clinical rationale for study. Melatonin secretion is related to migraine pathophysiology in many different ways.

Materials and methods.
The study was conducted in a group of 58 subjects (48 women and 10 men). The study group comprised 29 patients (24 women and five men) diagnosed with migraine according to the International Classification of Headache Disorders (ICHD-3 beta), within the framework of the Outpatient Clinic at Bielanski Hospital in Warsaw and the Clinical Department of Neurology of the 2nd Faculty of Medicine (now known as the Faculty of Medical Sciences) at the Medical University of Warsaw, Poland. The control group consisted of 29 subjects (24 women and five men) with no headache. Blood samples for the determination of melatonin were collected at midnight, 2am, 3am, 4am and 6am. Melatonin level in a frozen serum of venous blood was determined by a radio-immuno-enzymatic method at the Department of Histology and Embryology of the Faculty of Veterinary Medicine at the University of Warmia and Mazury in Olsztyn, Poland.

No statistically significant differences between the levels of melatonin and the averaged advances of melatonin profiles were observed in the examined and the control group. There were demonstrated medium negative correlations between the maximum value of melatonin and the duration of migraine (R = -0.4, p = 0.03). There were also observed statistically significant differences (p = 0.01) between the averaged advances of melatonin profiles, depending on the duration of migraine.

Conclusions and clinical implications.
Our study showed no abnormalities of melatonin secretion in patients with migraine during the interictal period. The results of studies available in the literature depend on the nature of the headache (episodic or chronic) and the time of measuring the concentration of melatonin (during a headache attack or in an interictal period).

Article available in PDF format

View PDF Download PDF file


  1. Gelfand AA, Goadsby PJ. The Role of Melatonin in the Treatment of Primary Headache Disorders. Headache. 2016; 56(8): 1257–1266.
  2. Meng X, Li Ya, Li S, et al. Dietary Sources and Bioactivities of Melatonin. Nutrients. 2017; 9(4).
  3. Słowińska-Klencka D, Lewiński A. Rola melatoniny w fizjologii i patologii człowieka. I. Dobowy rytm wydzielania melatoniny. Znaczenie melatoniny w fizjologii rozrodu. Melatonina a oś podwzgórze – przysadka – kora nadnerczy. Postępy Higieny i Medycyny Doświadczalnej. 1993; 47(3): 209–220.
  4. Claustrat B, Leston J. Melatonin: Physiological effects in humans. Neurochirurgie. 2015; 61(2-3): 77–84.
  5. Emens JS, Burgess HJ. Effect of Light and Melatonin and Other Melatonin Receptor Agonists on Human Circadian Physiology. Sleep Med Clin. 2015; 10(4): 435–453.
  6. Deshmukh VD. Retino-hypothalamic-pineal hypothesis in the pathophysiology of primary headaches. Med Hypotheses. 2006; 66(6): 1146–1151.
  7. Borgers AJ, Romeijn N, van Someren E, et al. Compression of the optic chiasm is associated with permanent shorter sleep duration in patients with pituitary insufficiency. Clin Endocrinol (Oxf). 2011; 75(3): 347–353.
  8. Zielonka D, Sowiński J, Nowak S, et al. Melatonin and cortisol profiles in patients with pituitary tumors. Neurol Neurochir Pol. 2015; 49(1): 65–69.
  9. Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int J Clin Pract. 2007; 61(5): 835–845.
  10. Pacchierotti C, Iapichino S, Bossini L, et al. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol. 2001; 22(1): 18–32.
  11. Lewiński A, Karbownik-Lewińska M. Znaczenie kliniczne i zastosowanie terapeutyczne melatoniny – obecny stan wiedzy. Folia Medica Lodziensia 2010; 37. ; 1: 111–150.
  12. Gelfand AA, Goadsby PJ. The Role of Melatonin in the Treatment of Primary Headache Disorders. Headache. 2016; 56(8): 1257–1266.
  13. Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014; 19(9): 1410–1418.
  14. Gonçalves AL, Martini Ferreira A, Ribeiro RT, et al. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 2016; 87(10): 1127–1132.
  15. Hou YC, Lai CH. The Relief Effects of Ramelteon on Refractory Chronic Migraine: A Case Report. Clin Psychopharmacol Neurosci. 2016; 14(4): 405–406.
  16. Guglielmo R, Martinotti G, Di Giannantonio M, et al. A possible new option for migraine management: agomelatine. Clin Neuropharmacol. 2013; 36(2): 65–67.
  17. Srinivasan V, Lauterbach EC, Ho KYu, et al. Melatonin in antinociception: its therapeutic applications. Curr Neuropharmacol. 2012; 10(2): 167–178.
  18. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005; 9(1): 11–24.
  19. Vgontzas A, Pavlović JM. Sleep Disorders and Migraine: Review of Literature and Potential Pathophysiology Mechanisms. Headache. 2018; 58(7): 1030–1039.
  20. Alstadhaug KB. Migraine and the Hypothalamus. Cephalalgia. 2009; 29(8): 809–817.
  21. Fraser S, Cowen P, Franklin M, et al. Direct radioimmunoassay for melatonin in plasma. Clin Chem. 1983; 29(2): 396–397.
  22. Peres MFP, Masruha MR, Zukerman E, et al. Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs. 2006; 15(4): 367–375.
  23. Gagnier JJ. The therapeutic potential of melatonin in migraines and other headache types. Altern Med Rev. 2001; 6(4): 383–389.
  24. Murialdo G, Fonzi S, Costelli P, et al. Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia. 1994; 14(3): 205–209.
  25. Peres MF, Sanchez del Rio M, Seabra ML, et al. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry. 2001; 71(6): 747–751.
  26. Masruha MR, de Souza Vieira DS, Minett TS, et al. Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. J Headache Pain. 2008; 9(4): 221–224.
  27. Kozak HH, Boysan M, Uca AU, et al. Sleep quality, morningness-eveningness preference, mood profile, and levels of serum melatonin in migraine patients: a case-control study. Acta Neurol Belg. 2017; 117(1): 111–119.
  28. Alstadhaug KB. Migraine and the Hypothalamus. Cephalalgia. 2009; 29(8): 809–817.
  29. Bruera O, Sances G, Leston J, et al. Plasma melatonin pattern in chronic and episodic headaches: evaluation during sleep and waking. Funct Neurol. 2008; 23(2): 77–81.

Neurologia i Neurochirurgia Polska